Pharma industry fiercely criticises Lundbeck fine
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Pharma industry fiercely criticises Lundbeck fine

The European Federation of Pharmaceutical Industries Associations (EFPIA) has criticised the European Commission’s decision to fine Lundbeck and other companies a total of €146 million

On Wednesday, Commissioner Joaquin Almunia said the Commission was fining nine companies over pay-for-delay agreements relating to Lundbeck’s anti-depressant drug citalopram (branded as Celexa or Cipramil).

Lundbeck was accused of paying generic rivals not to sell generic versions of the drug. It was fined €93.8 million. Other companies fined included Merck KGaA, Generics UK (part of Mylan) and Ranbaxy.

Lundbeck immediately said it would appeal the fine. “There is no question about the validity of Lundbeck's process patents at issue. Patent settlement agreements are efficiency enhancing and legitimate when there are bona fide grounds for dispute,” it said.

The EFPIA said it and its members were “concerned” about the decision, and added that it would prolong patent litigation and undermine confidence in the patent system.

EFPIA Director General Richard Bergström said: “The EU patent system is still a mess. It is no surprise that companies settle to save legal fees and uncertainty”. He called for a full policy debate in the Commission.

The European Generic Medicines Association did not immediately comment on the decision.

In his statement, Almunia said the “overwhelming majority” of patent settlement agreements are entirely legitimate, but ominously added: “Paying competitors to stay out of the market at the expense of European citizens has nothing to do with the legitimate protection of intellectual property: it is an illegal practice and the Commission will fight against it. We have other investigations ongoing and more decisions in this field are likely before the end of my mandate.”

The US Supreme Court last week ruled in a pay-for-delay case involving Actavis, saying that reverse-payment deals are not automatically illegal, and must be judged case-by-case.

more from across site and ros bottom lb

More from across our site

A 36-member team from Zhong Lun Law Firm, including six partners, will join the newly formed East IP Group
The Delhi High Court sided with Ericsson against Indian smartphone maker Lava, bringing the companies' nine-year dispute to a close
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Tennessee has passed the ELVIS Act, a law that fights against AI models that mimic the voice and likeness of music artists
Rob Stien, chief communications and public policy officer at InterDigital, says the EU has forgotten innovators while trying to solve an issue that doesn’t exist
As Australia’s Qantm IP leans towards being acquired by a private equity company, sources discuss what it could mean for IP firms
Law firms that are conscious of their role in society are more likely to win work, according to a survey of over 23,000 in-house professionals
Nghiem Xuan Bac Pham, managing partner of Vision & Associates, discusses opportunities created by the US-China rift as well as profitability issues facing IP practices
Douglas Leite and two of his colleagues were intrigued by Bhering Advogados’s mission to grow its patent litigation practice
Each week Managing IP speaks to a different IP practitioner about their life and career
Gift this article